Floatz logo

Acoramidis

Amyloidosis, Familial

Eidos Therapeutics, a BridgeBio companySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Amyloidosis, Familial cohort.

Asset / SponsorPhaseRating
Patisiran
Alnylam Pharmaceuticals
Phase 3A
Revusiran
Alnylam Pharmaceuticals
Phase 3BB
Patisiran
Alnylam Pharmaceuticals
Phase 3BB
Patisiran
Alnylam Pharmaceuticals
Phase 3BB
Revusiran
Alnylam Pharmaceuticals
Phase 3BB

View all 12 →

Same molecule, other indications

Acoramidis is also rated in:

amyloidosisDormant
BBB
Indicative ·
78 / 100
View asset →
Amyloid Cardiomyopathy, Transthyretin-RelatedDormant
BB
Indicative ·
66 / 100
View asset →
amyloidosisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →